M. Olid-Velilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
M. Olid-Velilla has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Aránzazu Díaz de Bustamante
Genetics Unit, Hospital Universitario de Móstoles, 28935 Madrid, Spain
1 shared publication - D. Perez-Torrella
Department of Laboratory of Clinical Analysis, Mostoles University Hospital, Madrid, Spain
1 shared publication - Jair Tenorio
Instituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz, 28046 Madrid, Spain
1 shared publication - María Teresa Darnaude
Genetics Department, Móstoles University Hospital, 28935 Madrid, Spain
1 shared publication - N. Torres-Pacho
Department of Internal Medicine, Mostoles University Hospital, Madrid, Spain
1 shared publication - Rafael Garcia-Carretero
Department of Internal Medicine, Hospital Universitario Severo Ochoa (Madrid, Spain)
1 shared publication
Latest Publications
- 22 February 2021
- Published by Springer Nature in Osteoporosis International
- Vol. 32 (9) , 1815-1824
Predictive modeling of hypophosphatasia based on a case series of adult patients with persistent hypophosphatasemia
Summary Approximately half of individuals with hypophosphatasemia (low levels of serum alkaline phosphatase) have hypophosphatasia, a rare genetic disease in which patients may have stress fractures, bone and joint pain, or premature tooth loss. We developed a predictive model based on specific biomarkers of this disease to better diagnose this condition. Introduction Hypophosphatasemia is a condition in which low levels of alkaline phosphatase (ALP) are detected in the serum. Some individuals presenting with this condition may have a rare genetic disease called hypophosphatasia (HPP), which involves mineralization of the bone and teeth. Lack of awareness of HPP and its nonspecific symptoms make this genetic disease difficult to diagnose. We developed a predictive model based on biomarkers of HPP such as ALP and pyridoxal 5′-phosphate (PLP), because clinical manifestations sometimes are not recognized as symptoms of HPP. Methods We assessed 325,000 ALP results between 2010 and 2015 to identify individuals suspected of having HPP. We performed univariate and multivariate analyses to characterize the relationship between hypophosphatasemia and HPP. Using several machine learning algorithms, we developed several models based on biomarkers and compared their performance to determine the best model. Results The final cohort included 45 patients who underwent a genetic test. Half (23 patients) showed a mutation of the ALPL gene that encodes the tissue-nonspecific ALP enzyme. ALP (odds ratio [OR] 0.61, 95% confidence interval [CI] 0.3–0.8, p = 0.01) and PLP (OR 1.06, 95% CI 1.01–1.15, p = 0.04) were the only variables significantly associated with the presence of HPP. Support vector machines and logistic regression were the machine learning algorithms that provided the best predictive models in terms of classification (area under the curve 0.936 and 0.844, respectively). Conclusions Given the high probability of a misdiagnosis, its nonspecific symptoms, and a lack of awareness of serum ALP levels, it is difficult to make a clinical diagnosis of HPP. Predictive models based on biomarkers are necessary to achieve a proper diagnosis. Our proposed machine learning approaches achieved reasonable performance compared to traditional statistical methods used in biomedicine, increasing the likelihood of properly diagnosing such a rare disease as HPP.
- 22 February 2021
- Published by Springer Nature in Osteoporosis International
- Vol. 32 (9) , 1815-1824
Predictive modeling of hypophosphatasia based on a case series of adult patients with persistent hypophosphatasemia
Summary Approximately half of individuals with hypophosphatasemia (low levels of serum alkaline phosphatase) have hypophosphatasia, a rare genetic disease in which patients may have stress fractures, bone and joint pain, or premature tooth loss. We developed a predictive model based on specific biomarkers of this disease to better diagnose this condition. Introduction Hypophosphatasemia is a condition in which low levels of alkaline phosphatase (ALP) are detected in the serum. Some individuals presenting with this condition may have a rare genetic disease called hypophosphatasia (HPP), which involves mineralization of the bone and teeth. Lack of awareness of HPP and its nonspecific symptoms make this genetic disease difficult to diagnose. We developed a predictive model based on biomarkers of HPP such as ALP and pyridoxal 5′-phosphate (PLP), because clinical manifestations sometimes are not recognized as symptoms of HPP. Methods We assessed 325,000 ALP results between 2010 and 2015 to identify individuals suspected of having HPP. We performed univariate and multivariate analyses to characterize the relationship between hypophosphatasemia and HPP. Using several machine learning algorithms, we developed several models based on biomarkers and compared their performance to determine the best model. Results The final cohort included 45 patients who underwent a genetic test. Half (23 patients) showed a mutation of the ALPL gene that encodes the tissue-nonspecific ALP enzyme. ALP (odds ratio [OR] 0.61, 95% confidence interval [CI] 0.3–0.8, p = 0.01) and PLP (OR 1.06, 95% CI 1.01–1.15, p = 0.04) were the only variables significantly associated with the presence of HPP. Support vector machines and logistic regression were the machine learning algorithms that provided the best predictive models in terms of classification (area under the curve 0.936 and 0.844, respectively). Conclusions Given the high probability of a misdiagnosis, its nonspecific symptoms, and a lack of awareness of serum ALP levels, it is difficult to make a clinical diagnosis of HPP. Predictive models based on biomarkers are necessary to achieve a proper diagnosis. Our proposed machine learning approaches achieved reasonable performance compared to traditional statistical methods used in biomedicine, increasing the likelihood of properly diagnosing such a rare disease as HPP.